Atea Pharmaceuticals, Inc. (AVIR)

Market Cap	486.00M +82.1%
Revenue (ttm)	n/a
Net Income	-158.35M
EPS	-1.94
Shares Out	79.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	507,416
Open	6.08
Previous Close	6.10
Day's Range	5.98 - 6.14
52-Week Range	2.46 - 6.45
Beta	0.26
Analysts	Buy
Price Target	8.00 (+31.15%)
Earnings Date	Mar 5, 2026

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 30, 2020
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: AVIR
• Website: https://ateapharma.com

Analyst Summary

According to 2 analysts, the average rating for AVIR stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 31.15% from the latest price.

Price Target

$8.0

(31.15% upside)

Analyst Consensus: Buy